JPRN-UMIN000004795已完成2 期
Treatment of Lambert-Eaton myasthenic syndrome with 3,4-diaminopyridin - Treatment of LEMS with diaminopyridin
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who are not able to comprehend the aim of the present study due to brain metastasis or metabolic encephalopathy are excluded.
研究者
相似试验
招募中
不适用
Treatment of Lambert-Eaton myasthenic syndrome with 3,4-diaminopyridiambert-Eaton myasthenic syndromeJPRN-UMIN000024055Tokushima University10
No Longer Available
不适用
Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAPLambert Eaton Myasthenic Syndrome (LEMS)NCT01378546Louis H. Weimer, MD
招募中
不适用
ambert-Eaton myasthenic syndrome: Clinical characteristics, pathogenesis and tumour associatio100038161002931710029107LEMSNL-OMON40297eids Universitair Medisch Centrum70
No Longer Available
不适用
3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)Lambert-Eaton Myasthenic Syndrome (LEMS)Congenital Myasthenia (CM)NCT02012933Oregon Health and Science University
进行中（未招募）
不适用
Traitement des syndromes myélodysplasiques par l'association aracytine et bortezomibMyelodysplastic syndrome (MDS) is a clonal disease of the bone marrow stem cells. The disease is frequently associated with cytopenia and/or blastosis. An evolution to an acute leukemia is not unfrequent (~ 30%). Treatments are very disapointing especially for high risk MDS. The prognosis mainly depends on blastosis, cytopenia and cytogenetic abnormalities but the disease is typically uncurable (except BMT).EUCTR2005-005794-29-BEGroupe français des Myélodysplasies39